Medexus Pharmaceuticals Inc. (TSX:MDP)
Canada · Delayed Price · Currency is CAD 4.960
-0.100 (-1.98%)
Aug 10, 2026, 3:59 PM EST
Medexus Pharmaceuticals Ratios and Metrics
Market cap in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 160 | 101 | 78 | 39 | 32 | 63 | |
Market Cap Growth | 81.25% | 28.78% | 98.25% | 21.95% | -48.46% | -58.62% |
Enterprise Value | 182 | 115 | 123 | 98 | 109 | 118 |
Last Close Price | 5.06 | 3.12 | 2.42 | 1.61 | 1.60 | 3.14 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 24.17 | - | 19.55 | - |
Forward PE | 12.30 | 7.48 | 19.63 | 5.21 | 43.87 | 43.87 |
PS Ratio | 1.16 | 0.73 | 0.50 | 0.26 | 0.22 | 0.65 |
PB Ratio | 2.34 | 1.47 | 1.04 | 0.96 | 1.06 | 2.82 |
P/FCF Ratio | 6.13 | 3.85 | 2.28 | 1.56 | - | - |
P/OCF Ratio | 6.08 | 3.82 | 2.26 | 1.55 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 1.31 | 0.83 | 0.79 | 0.64 | 0.74 | 1.23 |
EV/EBITDA Ratio | 8.38 | 5.34 | 4.53 | 3.91 | 5.59 | - |
EV/EBIT Ratio | 22.37 | 14.09 | 7.20 | 5.64 | 9.46 | - |
EV/FCF Ratio | 6.97 | 4.39 | 3.60 | 3.86 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.55 | 0.45 | 0.71 | 1.65 | 3.12 | 3.08 |
Debt / EBITDA Ratio | 1.56 | 1.43 | 1.95 | 2.68 | 4.81 | - |
Debt / FCF Ratio | 1.85 | 1.19 | 1.56 | 2.67 | - | - |
Net Debt / Equity Ratio | 0.44 | 0.32 | 0.25 | 1.47 | 2.54 | 2.52 |
Net Debt / EBITDA Ratio | 1.26 | 1.02 | 0.70 | 2.42 | 3.97 | -6.94 |
Net Debt / FCF Ratio | 1.48 | 0.84 | 0.55 | 2.39 | -37.88 | -35.12 |
Asset Turnover | 0.70 | 0.62 | 0.66 | 0.71 | 0.72 | 0.53 |
Inventory Turnover | 1.14 | 0.93 | 1.17 | 1.61 | 1.92 | 1.83 |
Quick Ratio | 0.41 | 0.40 | 0.38 | 0.44 | 0.43 | 0.51 |
Current Ratio | 1.30 | 1.19 | 0.83 | 1.10 | 0.87 | 1.02 |
Return on Equity (ROE) | -4.68% | -4.73% | 5.45% | -0.81% | 6.07% | -16.08% |
Return on Assets (ROA) | 3.00% | 2.29% | 4.55% | 5.04% | 3.53% | -5.38% |
Return on Invested Capital (ROIC) | 10.62% | 8.97% | 16.99% | -33.43% | 11.95% | -23.17% |
Return on Capital Employed (ROCE) | 7.30% | 6.20% | 16.00% | 14.30% | 10.90% | -13.60% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -2.09% | -3.32% | 4.14% | -0.74% | 5.12% | -5.74% |
FCF Yield | 16.31% | 25.99% | 43.91% | 64.18% | -6.31% | -2.54% |
Buyback Yield / Dilution | -21.91% | -21.91% | -18.76% | -8.76% | -3.36% | -30.65% |